Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.55 |
| ▸ | ACP1 | P24666 | 6/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.50 |
| ▸ | PTPRF | P10586 | 1/20 | 0.49 |
| ▸ | PTPRB | P23467 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542488 | 1.00 | PIM1 (1.00) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL2542486 | 1.00 | PIM1 (1.00) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL12259741 | 0.88 | PIM1 (0.79) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL12237152 | 0.87 | PIM1 (0.77) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL13797160 | 0.84 | PIM1 (0.72) | PIM1PTPN1ACP1ENPP2PTPN2 | |
| SCHEMBL5463878 | 0.78 | PIM1 (0.62) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL5463876 | 0.78 | PIM1 (0.62) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL17059998 | 0.77 | PIM1 (0.62) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL15682754 | 0.77 | PIM1 (0.62) | PIM1NLRP3PTPN1ACP1ENPP2 | |
| SCHEMBL28979066 | 0.76 | NLRP3 (0.71) | PIM1NLRP3PTPN1ACP1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2217235-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | Musc Foundation for Research Development (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009064486-A2 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885NLRP3 4566/4885PTPN1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.